Skip to main content
TipRanks
Go Ultimate75% OFF

Careium AB (CARE) AI Stock Analysis

1 Followers
SE:CARE

Careium AB

(Nasdaq OMX AB:CARE)

Select Model
Rating:69Neutral
Price Target:SEK 32.00â–²(5.96% Upside)
Action:reiterated
Date:10/24/26

The score is driven primarily by improving financial performance (profitability rebound and healthier leverage), supported by a positive technical trend with moderate momentum. Valuation is the main limiter, as a ~19 P/E with no dividend yield looks only fair relative to modest margins and uneven cash-flow consistency.

Positive Factors
Revenue RecoveryThe return to revenue growth indicates renewed demand and improving commercial execution after the prior dip. Sustained expansion would increase the installed base supporting service revenue, improve operating leverage, and strengthen Careium’s ability to reinvest in its telecare platform.
Negative Factors
Modest ProfitabilityAlthough profitability has rebounded, a roughly 4% net margin leaves limited room for cost increases or execution setbacks. The decline from stronger 2024 margins suggests operating leverage remains constrained, which may limit earnings growth even if revenue continues expanding.

Careium AB (CARE) vs. iShares MSCI Sweden ETF (EWD)

-30%-20%-10%0%10%20%30%SE:CARE+20.80%EWD+15.85%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 734.65M
Dividend Yield
―
Average Volume (3M)
16.32K
Price to Earnings (P/E)
14.8
Beta (1Y)
0.39
Revenue Growth
12.86%
EPS Growth
18.01%
Country
Sweden
Employees
613
Sector
General
Sector Strength
55
Industry
Security & Protection Services

Careium AB Business Overview & Revenue Model

Company Description

Careium AB (Publ), established in 1974 and headquartered in Malmö, Sweden, specializes in providing technologically advanced care solutions across numerous European nations, including Sweden, Norway, the United Kingdom, and the Netherlands. Their ext...

How the Company Makes Money

Careium makes money by selling and supporting telecare offerings that combine hardware and ongoing service delivery. Revenue is typically generated through: (1) service fees for operating telecare solutions, which can include hosting/operating the pl...

Careium AB Financial Statement Overview

Summary

Financials show a clear rebound with positive operating profit and net income plus renewed TTM revenue growth (~5%). Balance sheet leverage is manageable and improving (debt-to-equity ~0.29), but profitability remains modest (net margin ~4%) and cash flow consistency is a key risk given uneven cash conversion and prior volatility.

Income Statement

72Positive

Balance Sheet

78Positive

Cash Flow

64Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue961.70M854.10M870.70M824.60M725.10M587.50M
Gross Profit419.40M375.10M373.70M340.50M273.70M240.30M
EBITDA142.30M120.60M150.60M137.90M67.90M65.10M
Net Income50.60M35.80M58.40M37.90M-8.60M4.70M
Balance Sheet
Total Assets1.14B1.09B1.05B961.40M992.10M1.05B
Cash, Cash Equivalents and Short-Term Investments28.00M54.90M31.90M31.50M39.90M142.50M
Total Debt219.20M209.70M196.80M225.30M322.70M292.30M
Total Liabilities424.70M407.40M371.40M361.90M425.50M500.20M
Stockholders Equity717.70M681.50M678.20M599.50M566.60M551.50M
Cash Flow
Free Cash Flow63.50M51.30M36.90M61.90M-87.10M-70.90M
Operating Cash Flow131.90M143.40M92.90M111.90M-21.10M-19.80M
Investing Cash Flow-97.10M-102.20M-56.00M-50.00M-68.70M-163.70M
Financing Cash Flow-37.50M-13.70M-39.60M-69.70M-15.10M291.00M

Careium AB Technical Analysis

Technical Analysis SentimentPositive
Last Price30.20

Price Trends

50DMA27.97Positive
100DMA28.37Positive
200DMA25.50Positive

Market Momentum

MACD0.64Negative
RSI61.46Neutral
STOCH91.89Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CARE, the sentiment is Positive. The current price of 30.20 is above the 20-day moving average (MA) of 28.92, above the 50-day MA of 27.97, and above the 200-day MA of 25.50, indicating a bullish trend. The MACD of 0.64 indicates Negative momentum. The RSI at 61.46 is Neutral, neither overbought nor oversold. The STOCH value of 91.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CARE.

Careium AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:CARE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:DEDISE:DEDI72OutperformSEK 629.51M12.50―2.78%9.56%20.95%
SE:CARESE:CARE69NeutralSEK 734.65M14.80――12.86%18.01%
SE:PTRKSE:PTRK59NeutralSEK 178.06M-2.04――-10.30%-11.59%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:NNHSE:NNH51NeutralSEK 94.17M20.54―1.64%2.70%-43.94%
SE:BOULSE:BOUL41NeutralSEK 49.51M-2.84-58.52%―-16.09%78.68%

* General Sector Average

Performance Comparison

0%200%400%SE:CARESE:MVIRSE:BOULSE:NNHSE:DEDISE:PTRKDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:CARE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:CARECareium AB30.205.4021.77%
SE:MVIRMedivir1.130.70160.69%
SE:BOULBoule Diagnostics AB1.27-4.21-76.73%
SE:NNHNew Nordic Healthbrands AB15.20-6.64-30.42%
SE:DEDIDedicare AB63.0020.2647.39%
SE:PTRKPhysitrack Limited10.95-3.85-26.01%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 24, 2026